MeredithAnnMcKeanMDMPH

Oncology • Nashville, TN

Hematologic Oncology, Melanoma

Physician

Join to view full profile

Dr. McKean is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McKean's full profile

Already have an account?

Office
250 25th Ave N
Ste 200
Nashville, TN 37203
Phone+1 615-986-4366

Fax+1 615-320-1617

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2018
University of ColoradoResidency, Internal Medicine, 2012 - 2015
University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2012

Certifications & Licensure

FL State Medical License 2020 - Present
KY State Medical License 2023 - 2025
TN State Medical License 2018 - 2025
NC State Medical License 2020 - 2022
AL State Medical License 2020 - 2020
TX State Medical License 2015 - 2020
CO State Medical License 2012 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A.
Kyriakos P Papadopoulos, Meredith McKean, Silvia Goldoni, Isabelle Genvresse, Marine F Garrido
Clinical Cancer Research. 2024-12-16
A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors.
J Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik
Clinical Cancer Research. 2024-12-11
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study.
Oleksandr Dudnichenko, Konstantin Penkov, Meredith McKean, Mario Mandalà, Mariia Kukushkina
European Journal of Cancer. 2024-12-01

Press Mentions

5 Skin Cancer-Care Tools You Should Look Out ForApril 24th, 2023
IDEAYA Biosciences (IDYA) Reports Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C MeetingApril 24th, 2023
Tiragolumab plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-Positive Following ResectionSeptember 28th, 2021
Join now to see all